News - ANAVEX

View all Alzheimer's Disease Anavex2-73 Events News Releases PIPELINE Press Uncategorized

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

Anavex First-in-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease

Anavex Appoints Dr. Christopher Shackleton as an Advisor

Anavex to Hold Annual Meeting on April 11, 2011

Anavex Screening Healthy Volunteers for Phase I, First-in-Human Clinical Study in Alzheimer’s disease

Anavex Management to Hold Live Investor Conference Call Today at 4:30PM ET

Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease

Anavex Appoints Dr. Jeffrey Cummings to its Scientific Advisory Board

Anavex Appoints Independent Director

Anavex Appoints Dr. Rachelle Doody to Scientific Advisory Board